Pfizer Inc. (NYSE:PFE) Shares Sold by FARMERS & MERCHANTS TRUST Co OF LONG BEACH

FARMERS & MERCHANTS TRUST Co OF LONG BEACH lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 23.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,715 shares of the biopharmaceutical company's stock after selling 12,641 shares during the quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH's holdings in Pfizer were worth $1,080,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP grew its stake in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP purchased a new position in shares of Pfizer in the 2nd quarter valued at about $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer in the third quarter valued at about $35,000. Finally, Joseph Group Capital Management boosted its holdings in Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 771 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research reports. Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Finally, Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.

Pfizer Trading Down 0.7 %

Shares of Pfizer stock traded down $0.19 during trading hours on Friday, reaching $26.30. 35,146,711 shares of the company's stock were exchanged, compared to its average volume of 35,869,448. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a fifty day moving average of $26.09 and a 200-day moving average of $28.00. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the company earned ($0.17) EPS. The firm's quarterly revenue was up 31.2% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.54%. Pfizer's dividend payout ratio is 227.03%.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the business's stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company's stock, valued at $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.